Let me guess, no reply admitting the “argument” was factually inaccurate. Time to shelve it for a while to see if fear uncertainty and doubt can be sowed again with the same false narrative at a later date.
You do know that the DCVax-L results for methylated patients were no better than the 548 trial in methylated patients, right?
mOS was 32.1 in 548 placebo mOS was 30.2 in DC treatment methylated patients
By 4 years the DC arm would pull ahead some, but not enough to overcome the earlier numbers.
The 548 trial excluded biopsies and partial biopsies of under 20%. That makes it more inclusive the ECA patients but not as strict as the DC treatment arm.
News 
Market Data 
Discover 
AI
